Study the Mechanism and Effectiveness of Probiotics on Atopic Dermatitis
Condition(s) studied
Investigational drug(s) / intervention(s)
Probiotic 2 × 10^8: Capsule containing 2 × 10\^8 CFU \[TBC: per gram or per capsule\] of Bifidobacterium longum and Bifidobacterium bifidum \[TBC: final strains\] isolated from breast milk and healthy infant feces. Taken orally twice daily for 12 weeks; contents may be mixed with milk or juice at no more than 40 °C.
Placebo capsule: Capsule of identical appearance containing excipient only, without probiotic bacteria. Taken orally twice daily for 12 weeks.
Probiotic 2 × 10^10: Capsule containing 2 × 10\^10 CFU \[TBC: per gram or per capsule\] of Bifidobacterium longum and Bifidobacterium bifidum \[TBC: final strains\] isolated from breast milk and healthy infant feces. Taken orally twice daily for 12 weeks; contents may be mixed with milk or juice at no more than 40 °C.
Study summary
The goal of this clinical trial is to learn whether probiotics isolated from breast milk and healthy infant feces can reduce the severity of atopic dermatitis (eczema) in children aged 3 to 18 years with moderate-to-severe disease. The main questions it aims to answer are:
* Does taking the probiotic capsule twice daily for 12 weeks reduce eczema severity, measured by the EASI SCORAD?
* Does the probiotic improve quality of life, blood markers of allergic inflammation (IgE, histamine, IL-31, T-cell subsets), and gut microbiota composition? Researchers will compare the probiotic to a placebo capsule that looks the same but contains no probiotic bacteria.
Participants will:
* Take one capsule twice daily for 12 weeks, in addition to their usual atopic dermatitis treatment
* Complete the PO-SCORAD and a quality-of-life questionnaire at baseline and weeks 2, 4, 8 and 12
* Provide stool samples at baseline and weeks 4 and 12, and a 10 mL blood sample at baseline and week 12.
Eligibility
Primary outcome measure(s)
- Change in Eczema Area and Severity Index (EASI) score from baseline to week 12 — Baseline, week4, week8, week 12
Clinician-assessed EASI. Score range 0-72; higher scores indicate more severe disease. - Change in gut microbial — Baseline, weeks 4 and 12
Relative abundance (%) of the gut microbial from 16S rRNA gene (V1-V9) sequencing of stool. - Change in PO-SCORAD — Baseline, week4, week8, week 12
Patient-Oriented SCORAD completed by the participant or primary caregiver (range 0-103; higher = worse). - Change in quality of life — Baseline, week4, week8, week 12
For different ages, IDQOL, CDLQI, or DLQI, completed by the participant or primary caregiver.(range:0-30) - Change in serum total IgE — Baseline and week 12
Serum total IgE concentration (IU/mL). - Change in serum histamine — Baseline and week 12
Serum histamine concentration measured by ELISA (ng/mL). - Change in serum IL-4 — Baseline and week 12
Serum interleukin-4 concentration measured by ELISA (pg/mL). - Change in serum IL-13 — Baseline and week 12
Serum interleukin-13 concentration measured by ELISA (pg/mL). - Change in serum IL-31 — Baseline and week 12
Serum interleukin-31 concentration measured by ELISA (pg/mL). - Change in white blood cell count — Baseline and week 12
Total white blood cell count from complete blood count (cells/μL). - Change in absolute lymphocyte count — Baseline and week 12
Absolute lymphocyte count (cells/μL). - Change in absolute CD3+ T-cell count — Baseline and week 12
Absolute CD3+ T-cell count measured by flow cytometry (cells/μL). - Change in absolute CD4+ helper T-cell count — Baseline and week 12
Absolute CD4+ T-cell count measured by flow cytometry (cells/μL). - Change in absolute CD8+ suppressor/cytotoxic T-cell count — Baseline and week 12
Absolute CD8+ T-cell count measured by flow cytometry (cells/μL). - Change in CD4+/CD8+ T-cell ratio — Baseline and week 12
Ratio of CD4+ to CD8+ T cells measured by flow cytometry (ratio, unitless).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| National Cheng Kung University Hospital | Tainan | Taiwan |
More National Cheng-Kung University Hospital trials in Taiwan
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07937592 on ClinicalTrials.gov ↗ ← All trials in Taiwan